{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:30:03Z","timestamp":1789846203952,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04222-9","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T03:56:02Z","timestamp":1770868562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced folate carrier 1 G80A polymorphism is correlated with elevated methotrexate-induced toxicity in pediatric acute lymphoblastic leukemia patients: a systemic meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Yihuan","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"11","key":"4222_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524\u201339.","journal-title":"Haematologica"},{"key":"4222_CR2","volume-title":"PDQ Cancer Information Summaries","author":"Board PPTE","year":"2002","unstructured":"Board PPTE. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002."},{"issue":"1","key":"4222_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen SJ, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024;10(1):41.","journal-title":"Nat Rev Dis Primers"},{"key":"4222_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/children11111329","author":"A Ray","year":"2024","unstructured":"Ray A, Levitt M, Efunkoya T, Trinkman H. Precision medicine for acute lymphoblastic leukemia in children: a review. Children. 2024. https:\/\/doi.org\/10.3390\/children11111329.","journal-title":"Children"},{"issue":"2","key":"4222_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","volume":"23","author":"H Inaba","year":"2025","unstructured":"Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, et al. Pediatric acute lymphoblastic Leukemia, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(2):41\u201362.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4222_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11899-017-0376-z","volume":"12","author":"RR Maxwell","year":"2017","unstructured":"Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(3):176\u201386.","journal-title":"Curr Hematol Malig Rep"},{"key":"4222_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165869","author":"MM Mitura-Lesiuk","year":"2025","unstructured":"Mitura-Lesiuk MM, Dubaj M, Bigosi\u0144ski K, Raniewicz M. The role of miRNAs as predictors of acute lymphoblastic leukemia chemotherapy toxicity in children: a systematic review. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14165869.","journal-title":"J Clin Med"},{"key":"4222_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040723","author":"H Hayashi","year":"2024","unstructured":"Hayashi H, Makimoto A, Yuza Y. Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16040723.","journal-title":"Cancers"},{"issue":"1","key":"4222_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/07357909109032800","volume":"9","author":"OG Jonsson","year":"1991","unstructured":"Jonsson OG, Kamen BA. Methotrexate and childhood leukemia. Cancer Invest. 1991;9(1):53\u201360.","journal-title":"Cancer Invest"},{"issue":"4","key":"4222_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/hematolrep15040065","volume":"15","author":"V Karpa","year":"2023","unstructured":"Karpa V, Kalinderi K, Fidani L, Tragiannidis A. Association of MicroRNA polymorphisms with toxicities induced by methotrexate in children with acute lymphoblastic leukemia. Hematol Rep. 2023;15(4):634\u201350.","journal-title":"Hematol Rep"},{"key":"4222_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105515","author":"P \u015aliwa-Tytko","year":"2022","unstructured":"\u015aliwa-Tytko P, Kaczmarska A, Lejman M, Zawitkowska J. Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23105515.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4222_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2469373","volume":"30","author":"X Yan","year":"2025","unstructured":"Yan X, Zhang N, Wang G, Wang J. Association between ABCB1 C3435 T polymorphism- and methotrexate-related toxicity in pediatric acute lymphoblastic leukemia: a meta-analysis. Hematology. 2025;30(1):2469373.","journal-title":"Hematology"},{"issue":"5","key":"4222_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41397-023-00303-0","volume":"23","author":"T Harju","year":"2023","unstructured":"Harju T, Hurme-Niiranen A, Suo-Palosaari M, Nygaard Nielsen S, Hinttala R, Schmiegelow K, et al. DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship? Pharmacogenomics J. 2023;23(5):105\u201311.","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"4222_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/phar.2779","volume":"43","author":"M Zobeck","year":"2023","unstructured":"Zobeck M, Bernhardt MB, Kamdar KY, Rabin KR, Lupo PJ, Scheurer ME. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023;43(3):205\u201314.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4222_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/FPC.0000000000000563","volume":"35","author":"SM Wang","year":"2025","unstructured":"Wang SM, Zhao DQ, Kong XY, Li M. The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2025;35(4):127\u201335.","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"4222_CR16","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1097\/MPH.0000000000003075","volume":"47","author":"AL Walz","year":"2025","unstructured":"Walz AL, Kocherginsky M, Newmark M, Brooks E, Walterhouse D. Iohexol clearance and biomarker analysis to predict toxicity in patients with acute lymphoblastic leukemia and lymphoma receiving high-dose methotrexate. J Pediatr Hematol Oncol. 2025;47(6):e235-40.","journal-title":"J Pediatr Hematol Oncol"},{"key":"4222_CR17","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.2147\/DDDT.S516431","volume":"19","author":"WC Dong","year":"2025","unstructured":"Dong WC, Gao SS, Shi B, Li HR, Jiang Y, Guo JL, et al. Simultaneous determination of unbound plasma concentration of methotrexate and 7-hydroxymethotrexate in children patients receiving high-dose methotrexate therapy. Drug Des Devel Ther. 2025;19:4383\u201396.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4222_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/phar.4638","volume":"45","author":"RD Harris","year":"2025","unstructured":"Harris RD, Taylor OA, Gramatges MM, Hughes AE, Zobeck M, Pruitt S, et al. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025;45(1):4\u201311.","journal-title":"Pharmacotherapy"},{"key":"4222_CR19","doi-asserted-by":"publisher","first-page":"1069321","DOI":"10.3389\/fphar.2022.1069321","volume":"13","author":"K Sato","year":"2022","unstructured":"Sato K, Seki T, Mizutani A, Muranaka Y, Hirota S, Nishi K, et al. A single high-dose irradiation changes accumulation of methotrexate and gene expression levels of SLC and ABC transporters in cancer cells. Front Pharmacol. 2022;13:1069321.","journal-title":"Front Pharmacol"},{"issue":"7929","key":"4222_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41586-022-05168-0","volume":"609","author":"NJ Wright","year":"2022","unstructured":"Wright NJ, Fedor JG, Zhang H, Jeong P, Suo Y, Yoo J, et al. Methotrexate recognition by the human reduced folate carrier SLC19A1. Nature. 2022;609(7929):1056\u201362.","journal-title":"Nature"},{"issue":"29","key":"4222_CR21","doi-asserted-by":"publisher","first-page":"17468","DOI":"10.1074\/jbc.270.29.17468","volume":"270","author":"SC Wong","year":"1995","unstructured":"Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem. 1995;270(29):17468\u201375.","journal-title":"J Biol Chem"},{"issue":"2","key":"4222_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0304-3835(97)00464-3","volume":"124","author":"H Kobayashi","year":"1998","unstructured":"Kobayashi H, Takemura Y, Ohnuma T. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates. Cancer Lett. 1998;124(2):135\u201342.","journal-title":"Cancer Lett"},{"issue":"6","key":"4222_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2174\/1381612825666190329141003","volume":"25","author":"YH Hu","year":"2019","unstructured":"Hu YH, Zhou L, Wang SS, Jing X, Guo HL, Sun F, et al. Methotrexate disposition in pediatric patients with acute lymphoblastic leukemia: what have we learnt from the genetic variants of drug transporters. Curr Pharm Des. 2019;25(6):627\u201334.","journal-title":"Curr Pharm Des"},{"issue":"16","key":"4222_CR24","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2003.07.056","volume":"21","author":"S Kishi","year":"2003","unstructured":"Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21(16):3084\u201391.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4222_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","volume":"86","author":"S Pakakasama","year":"2007","unstructured":"Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86(8):609\u201311.","journal-title":"Ann Hematol"},{"issue":"35","key":"4222_CR26","first-page":"2739","volume":"20","author":"J Xu","year":"2009","unstructured":"Xu J, Xu KK, Li TY, Gu HJ, Liao QC, Yang L. Association between RFC1 G80A polymorphism and plasma concentration and adverse reactions of methotrexate in children with acute lymphoblastic leukemia. J China Pharm. 2009;20(35):2739\u201341.","journal-title":"J China Pharm"},{"issue":"21","key":"4222_CR27","first-page":"1674","volume":"24","author":"KK Xu","year":"2009","unstructured":"Xu KK, Liao QC, Zhang Y, Xu J, Luo L, Wang CX, et al. Influence of MTHFR C677T and RFC1 G80A gene polymorphisms on adverse reactions of high dose methotrexate chemotherapy in children with acute lymphoblastic leukemia. J Appl Clin Pediatr. 2009;24(21):1674\u201376.","journal-title":"J Appl Clin Pediatr"},{"issue":"4","key":"4222_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3109\/10428191003611402","volume":"51","author":"B Faganel Kotnik","year":"2010","unstructured":"Faganel Kotnik B, Dolzan V, Grabnar I, Jazbec J. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2010;51(4):724\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4222_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pi\u00f1an MA, Garcia-Miguel P, Navajas A, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(4):612\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"4222_CR30","first-page":"1376","volume":"34","author":"H Li","year":"2014","unstructured":"Li H, Jiang H, Liu Q. Correlation between genetic polymorphism of RFC1 gene and therapeutic reaction of high dose methotrexate. J Shanghai Jiaotong Univ. 2014;34(9):1376\u201380.","journal-title":"J Shanghai Jiaotong Univ"},{"issue":"23","key":"4222_CR31","doi-asserted-by":"publisher","first-page":"37761","DOI":"10.18632\/oncotarget.17781","volume":"8","author":"SG Liu","year":"2017","unstructured":"Liu SG, Gao C, Zhang RD, Zhao XX, Cui L, Li WJ, et al. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017;8(23):37761\u201372.","journal-title":"Oncotarget"},{"issue":"5","key":"4222_CR32","first-page":"35","volume":"31","author":"YJ Cui","year":"2019","unstructured":"Cui YJ, Wang SM, Jin ZG. Relationship between polymorphism of reduced folate carrier gene with chemotherapy response to high dose methotrexate. Med Pharm J Chin Peoples Liberation Army. 2019;31(5):35\u20138.","journal-title":"Med Pharm J Chin Peoples Liberation Army"},{"issue":"10","key":"4222_CR33","first-page":"1611","volume":"34","author":"Y Wang","year":"2019","unstructured":"Wang Y, Li F, Cao J. Analysis of the characteristics and influencing factors of adverse reactions in patients with acute lymphoblastic leukemia treated by methotrexate. Pract J Cancer. 2019;34(10):1611\u20134.","journal-title":"Pract J Cancer"},{"issue":"6","key":"4222_CR34","first-page":"800","volume":"23","author":"MA Esmaili","year":"2020","unstructured":"Esmaili MA, Kazemi A, Faranoush M, Mellstedt H, Zaker F, Safa M, et al. Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020;23(6):800\u201309.","journal-title":"Iran J Basic Med Sci"},{"issue":"3","key":"4222_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00280-022-04405-7","volume":"89","author":"R Ramalingam","year":"2022","unstructured":"Ramalingam R, Kaur H, Scott JX, Sneha LM, Arunkumar G, Srinivasan A, et al. Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients. Cancer Chemother Pharmacol. 2022;89(3):393\u2013400.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4222_CR36","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1080\/10428194.2025.2451059","volume":"66","author":"M Li","year":"2025","unstructured":"Li M, Zhao DQ, Kong XY, Wang SM. Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. Leuk Lymphoma. 2025;66(6):1068\u201378.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"4222_CR37","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3109\/10428194.2014.898761","volume":"55","author":"HR He","year":"2014","unstructured":"He HR, Liu P, He GH, Dong WH, Wang MY, Dong YL, et al. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma. 2014;55(12):2793\u2013800.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4222_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.mph.0000198269.61948.90","volume":"28","author":"N Shimasaki","year":"2006","unstructured":"Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006;28(2):64\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"4222_CR39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011;67(10):993\u20131006.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4222_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1515\/raon-2017-0040","volume":"51","author":"BF Kotnik","year":"2017","unstructured":"Kotnik BF, Jazbec J, Grabar PB, Rodriguez-Antona C, Dolzan V. Association between SLC19A1 gene polymorphism and high dose methotrexate toxicity in childhood acute lymphoblastic leukaemia and non hodgkin malignant lymphoma: introducing a haplotype based approach. Radiol Oncol. 2017;51(4):455\u201362.","journal-title":"Radiol Oncol"},{"issue":"2","key":"4222_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10038-006-0096-z","volume":"52","author":"H Imanishi","year":"2007","unstructured":"Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166\u201371.","journal-title":"J Hum Genet"},{"key":"4222_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111797","author":"L Calzetta","year":"2022","unstructured":"Calzetta L, Aiello M, Frizzelli A, Camardelli F, Cazzola M, Rogliani P, et al. Stem cell-based regenerative therapy and derived products in COPD: a systematic review and meta-analysis. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11111797.","journal-title":"Cells"},{"issue":"2","key":"4222_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.5114\/aoms.2018.73091","volume":"15","author":"T Zara-Lopes","year":"2019","unstructured":"Zara-Lopes T, Galbiatti-Dias ALS, Castanhole-Nunes MMU, Padovani-J\u00fanior JA, Maniglia JV, Pavarino EC, et al. Polymorphisms in MTHFR, MTR, RFC1 and C\u00dfS genes involved in folate metabolism and thyroid cancer: a case-control study. Arch Med Sci. 2019;15(2):522\u201330.","journal-title":"Arch Med Sci"},{"issue":"4","key":"4222_CR44","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1007\/s11033-011-1285-1","volume":"39","author":"CB Rde C","year":"2012","unstructured":"Carvalho Barbosa Rde C, Menezes DC, Freire TF, Sales DC, Alencar VH, Rabenhorst SH. Associations of polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent. Mol Biol Rep. 2012;39(4):4899\u2013907.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"4222_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/gtmb.2014.0177","volume":"19","author":"R Montalv\u00e3o-de-Azevedo","year":"2015","unstructured":"Montalv\u00e3o-de-Azevedo R, Vasconcelos GM, Vargas FR, Thuler LC, Pombo-de-Oliveira MS, de Camargo B. RFC-1 80G\u2009>\u2009A polymorphism in case-mother\/control-mother dyads is associated with risk of nephroblastoma and neuroblastoma. Genet Test Mol Biomarkers. 2015;19(2):75\u201381.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"5","key":"4222_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/00365510701805431","volume":"68","author":"V Ekl\u00f6f","year":"2008","unstructured":"Ekl\u00f6f V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Palmqvist R. The reduced folate carrier (RFC1) 80G\u2009>\u2009A and folate hydrolase 1 (FOLH1) 1561C\u2009>\u2009T polymorphisms and the risk of colorectal cancer: a nested case-referent study. Scand J Clin Lab Invest. 2008;68(5):393\u2013401.","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"4222_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.7150\/jca.13303","volume":"7","author":"X Huang","year":"2016","unstructured":"Huang X, Gao Y, He J, Cai J, Ta N, Jiang H, et al. The association between RFC1 G80A polymorphism and cancer susceptibility: evidence from 33 studies. J Cancer. 2016;7(2):144\u201352.","journal-title":"J Cancer"},{"issue":"8","key":"4222_CR48","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3324\/haematol.2010.022095","volume":"95","author":"J Vijayakrishnan","year":"2010","unstructured":"Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 2010;95(8):1405\u201314.","journal-title":"Haematologica"},{"issue":"1","key":"4222_CR49","first-page":"52","volume":"6","author":"M Forat-Yazdi","year":"2016","unstructured":"Forat-Yazdi M, Hosseini-Biouki F, Salehi J, Neamatzadeh H, Masoumi Dehshiri R, Sadri Z, et al. Association between RFC1 G80A polymorphism and acute lymphoblastic leukemia: a review and Meta-Analysis of 10 studies. Iran J Ped Hematol Oncol. 2016;6(1):52\u201363.","journal-title":"Iran J Ped Hematol Oncol"},{"issue":"10","key":"4222_CR50","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17460441.2023.2244760","volume":"18","author":"V Dvorak","year":"2023","unstructured":"Dvorak V, Superti-Furga G. Structural and functional annotation of solute carrier transporters: implication for drug discovery. Expert Opin Drug Discov. 2023;18(10):1099\u2013115.","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"4222_CR51","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.tibs.2023.05.011","volume":"48","author":"A Schlessinger","year":"2023","unstructured":"Schlessinger A, Zatorski N, Hutchinson K, Colas C. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Trends Biochem Sci. 2023;48(9):801\u201314.","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"4222_CR52","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1021\/acs.jmedchem.9b01237","volume":"63","author":"WW Wang","year":"2020","unstructured":"Wang WW, Gallo L, Jadhav A, Hawkins R, Parker CG. The druggability of solute carriers. J Med Chem. 2020;63(8):3834\u201367.","journal-title":"J Med Chem"},{"issue":"1","key":"4222_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12016-025-09095-6","volume":"68","author":"Y Chen","year":"2025","unstructured":"Chen Y, Peng C, Chen X, Li J. The role of solute carriers in the metabolic reprogramming of skin diseases. Clin Rev Allergy Immunol. 2025;68(1):80.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4222_CR54","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5465","author":"B Quaresima","year":"2025","unstructured":"Quaresima B, Scicchitano S, Faniello MC, Mesuraca M. Role of solute carrier transporters in ovarian cancer (Review). Int J Mol Med. 2025. https:\/\/doi.org\/10.3892\/ijmm.2024.5465.","journal-title":"Int J Mol Med"},{"key":"4222_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12030063","author":"R Bharadwaj","year":"2024","unstructured":"Bharadwaj R, Jaiswal S, de la Velarde Cruz EE, Thakare RP. Targeting solute carrier transporters (SLCs) as a therapeutic target in different cancers. Diseases. 2024. https:\/\/doi.org\/10.3390\/diseases12030063.","journal-title":"Diseases"},{"issue":"5","key":"4222_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/cpt.1185","volume":"104","author":"S Hu","year":"2018","unstructured":"Hu S, Sprowl JA. Strategies to reduce solute Carrier-Mediated toxicity. Clin Pharmacol Ther. 2018;104(5):799\u2013802.","journal-title":"Clin Pharmacol Ther"},{"key":"4222_CR57","first-page":"27","volume":"7","author":"JJG Marin","year":"2024","unstructured":"Marin JJG, Serrano MA, Herraez E, Lozano E, Ortiz-Rivero S, Perez-Silva L, et al. Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy. Cancer Drug Resist. 2024;7:27.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"4222_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12957-023-03287-0","volume":"22","author":"B Liu","year":"2024","unstructured":"Liu B, Liu G, Liu B, Guo Y, Peng N, Li T. Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):19.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"4222_CR59","first-page":"225","volume":"1","author":"RP Torres","year":"2022","unstructured":"Torres RP, Santos FP, Branco JC. Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis. ARP Rheumatol. 2022;1(3):225\u20139.","journal-title":"ARP Rheumatol"},{"issue":"4","key":"4222_CR60","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1124\/dmd.113.055723","volume":"42","author":"LH Matherly","year":"2014","unstructured":"Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab Dispos. 2014;42(4):632\u201349.","journal-title":"Drug Metab Dispos"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04222-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:02:39Z","timestamp":1774022559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04222-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4222"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04222-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}